APPALANAIDU SASAPU M.D NPI 1699936252

NPI Details

Appalanaidu Sasapu, M.D is a hematology and oncology internal medicine in Little Rock, AR with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Appalanaidu Sasapu, M.D NPI is 1699936252. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

8901 CARTI WAY
LITTLE ROCK, AR
ZIP 72205-523
Phone: (501) 906-3000
Fax: (501) 526-6562

The NPI 1699936252 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Unclassified drugs (HCPCS:J3490)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Protein measurement, serum (HCPCS:84165)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Uric acid level, blood (HCPCS:84550)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Blood test, clotting time (HCPCS:85610)
• Magnesium level (HCPCS:83735)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Nephelometry, test method using light (HCPCS:83883)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Phosphate level (HCPCS:84100)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Erythropoietin (protein) level (HCPCS:82668)
• Injection of drug or substance into vein (HCPCS:96374)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 6/17/2008 and was last updated on 6/10/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: